Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR3 | O14843 | 1/20 | 0.37 |
| ▸ | KRAS | P01116 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.32 |
| ▸ | GRIN1 | Q05586 | 3/20 | 0.31 |
| ▸ | GRIN2A | Q12879 | 3/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.31 |
| ▸ | GRIN2D | O15399 | 2/20 | 0.31 |
| ▸ | GRIN3B | O60391 | 2/20 | 0.31 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.31 |
| ▸ | GRIN2C | Q14957 | 2/20 | 0.31 |
| ▸ | GRIN3A | Q8TCU5 | 2/20 | 0.31 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.31 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8078206 | 0.98 | FFAR3 (0.36) | FFAR3KRASPOLBALDH1A1AKR1C1 | |
| SCHEMBL1399847 | 0.93 | KRAS (0.41) | FFAR3KRASPOLBCYP1A2 | |
| SCHEMBL20581854 | 0.93 | KRAS (0.41) | FFAR3KRASPOLBCYP1A2 | |
| SCHEMBL7763991 | 0.85 | GRIN1 (0.33) | POLBALDH1A1GRIN1GRIN2ASLC6A4 | |
| SCHEMBL3121522 | 0.83 | POLB (0.37) | POLBALDH1A1GRIN1GRIN2ASLC6A4 | |
| SCHEMBL7550154 | 0.78 | NPSR1 (0.41) | GRIN1GRIN2AGRIN2BCYP2C19 | |
| SCHEMBL16407725 | 0.78 | POLB (0.32) | POLB | |
| SCHEMBL28218027 | 0.78 | NPSR1 (0.41) | GRIN1GRIN2AGRIN2BCYP2C19 | |
| SCHEMBL19388527 | 0.78 | GRIN2D (0.34) | POLBGRIN1GRIN2AGRIN2DGRIN3B | |
| SCHEMBL16391146 | 0.78 | CYP19A1 (0.33) | POLBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230400766-A1 | ONIUM SALT, RESIST COMPOSITION AND PATTERN FORMING PROCESS | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2023-12-14 | — | — | US | disclosed |
| US-10881700-B1 | Compositions including extracts of gray mangrove leaves and methods of treatment using such compositions in treatment of viral infections | KING ABDULLAH UNIVERSITY OF SCIENCE AND TECHNOLOGY (SA) | 2021-01-05 | — | — | US | disclosed |
| EP-3426391-A1 | COMPOSITIONS AND METHODS FOR ACYLATING LACTAMS | California Institute of Technology (US) | 2019-01-16 | — | — | EP | disclosed |
| CN-104940202-B | Inhibitors of influenza viruses replication | 沃泰克斯药物股份有限公司 | 2018-10-16 | — | — | CN | disclosed |
| EP-3019196-B1 | COMBINATIONS OF HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-06-06 | — | — | EP | disclosed |
| US-9770439-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-09-26 | — | — | US | disclosed |
| US-9770439-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-09-26 | — | — | US | disclosed |
| US-9770439-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-09-26 | — | — | US | disclosed |
| WO-2017156239-A1 | COMPOSITIONS AND METHODS FOR ACYLATING LACTAMS | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2017-09-14 | — | — | WO | disclosed |
| US-20160158200-A1 | Combinations of Hepatitis C Virus Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2016-06-09 | — | — | US | disclosed |
| EP-2651940-A1 | INHIBITORS OF INFLUENZA VIRUSES REPLICATION | Vertex Pharmaceuticals Incorporated (US) | 2013-10-23 | — | — | EP | disclosed |
| EP-2651941-A1 | INHIBITORS OF INFLUENZA VIRUSES REPLICATION | Vertex Pharmaceuticals Incorporated (US) | 2013-10-23 | — | — | EP | disclosed |
| EP-2485737-A1 | NOVEL TRPA1 ANTAGONISTS | Merck Sharp & Dohme Corp. (US) | 2012-08-15 | — | — | EP | disclosed |
| US-20120196894-A1 | NOVEL TRPA1 ANTAGONISTS | SCHERING CORPORATION | 2012-08-02 | — | — | US | disclosed |
| WO-2012083117-A1 | INHIBITORS OF INFLUENZA VIRUSES REPLICATION | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-06-21 | — | — | WO | disclosed |
| WO-2012083121-A1 | INHIBITORS OF INFLUENZA VIRUSES REPLICATION | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-06-21 | — | — | WO | disclosed |
| EP-2448942-A1 | FUSED TRICYCLIC COMPOUNDS AS NOVEL mTOR INHIBITORS | Schering Corporation (US) | 2012-05-09 | — | — | EP | disclosed |
| WO-2011043954-A1 | NOVEL TRPA1 ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2011-04-14 | — | — | WO | disclosed |
| CN-101827842-A | Oxadiazole derivatives as dgat inhibitors | ASTRAZENECA AB | 2010-09-08 | — | — | CN | disclosed |
| US-4959293-A | Deep UV photoresist with alkyl 2-diazo-1-ones as solubility modification agents | J. T. BAKER, INC. (US) | 1990-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160158200-A1 | Combinations of Hepatitis C Virus Inhibitors | HAVCR2, EIF2AK2, MAVS | FFAR3 4255/4885KRAS 819/4885POLB 1787/4885 |
| US-20120196894-A1 | NOVEL TRPA1 ANTAGONISTS | TRPA1, TRPV1, TRPV2 | FFAR3 339/4885KRAS 2142/4885POLB 4859/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.